Market Overview:
Circulating cell-free tumor DNA (ctDNA) refers to small fragments of tumor DNA shed from dying tumor cells that circulate in the bloodstream and can be isolated and analyzed. ctDNA testing provides a non-invasive liquid biopsy option in cancer diagnosis and monitoring.
The global Circulating Cell-Free Tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 22.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the circulating cell-free tumor DNA market is the increasing adoption of liquid biopsy for cancer monitoring and recurrence detection. ctDNA testing allows frequent real-time monitoring of a patient's tumor during and after treatment using simple blood draws. This non-invasive approach enables early detection of disease recurrence or progression as compared to imaging scans. Growing preference for minimal invasive testing procedures is expected to drive the demand for ctDNA assays over the forecast period.
Segment Analysis
The circulating cell-free tumor DNA market is dominated by the liquid biopsy segment. Liquid biopsy is a type of non-invasive test that analyzes bio fluids such as blood collected from cancer patients to detect the presence of circulating tumor DNA (ctDNA). It has emerged as an effective alternative to invasive tissue biopsies. Liquid biopsy allows real-time monitoring of tumor DNA levels during treatment, thereby allowing physicians to detect early recurrence and progression. The non-invasive nature of liquid biopsy and its ability to offer frequent tumor monitoring throughout the treatment process has led to its widespread adoption over tissue biopsies. This has driven the growth of the liquid biopsy segment in the circulating cell-free tumor DNA market.
Key Takeaways
The Global Circulating Cell-Free Tumor DNA Market Size is expected to witness high growth, exhibiting a CAGR of 22.9% over the forecast period, due to increasing demand for non-invasive early cancer detection methods.
Regional analysis
North America is dominating the circulating cell-free tumor DNA market currently due to the growing need for advanced cancer diagnostics and presence of leading NGS companies. However, Asia Pacific is poised to grow at the fastest pace during the forecast period supported by increasing healthcare expenditure and focus on cancer diagnostics & research in emerging countries such as China and India.
Key players
Key players operating in the circulating cell-free tumor DNA market are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
For More Insights, Read: https://www.newsstatix.com/circulating-cell-free-tumor-dna-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment